International Journal of Drug Policy
Volume 13, Issue 5 , Pages 341-347, November 2002

Sociopharmacology of drug use: initial thoughts

  • Samuel R Friedman

      Affiliations

    • National Development and Research Institutes, Inc., 71 West 23rd Street, New York, NY 10010, USA
    • Corresponding Author InformationCorresponding author. Fax: +1-917-438-894

Received 21 May 2001; received in revised form 1 May 2002; accepted 3 May 2002.

Abstract 

Psychopharmacological approaches to drug use focus on psychological traits of drug users and chemical traits of drugs. Whether through medicalisation or demonisation, this defines users as the problem, which ignores socioeconomic and other issues that make individuals, neighbourhoods, and population groups vulnerable to harmful drug use. We discuss a concept of ‘sociopharmacology of drug use’ that locates drug use in broader contexts. This discussion suggests that (a) data on drug-related harm point to the ills and contradictions of society. (b) If anything is to be demonised, a sociopharmacological view suggests that it be the social order, not the individual user. (c) Nonetheless, current drug use patterns cause a lot of misery to drug users, their families, and their neighbours. Research and programs are needed to reduce these harms. (d) Laws that punish users and dealers are at best based on misdiagnosis of the roots of the problem, and can serve to scapegoat the vulnerable. (e) Research should trace how social, economic and health policies create conditions that increase harmful drug use, as well as develop better ways to provide resources to individuals and communities with which to ameliorate conditions that lead to harmful drug use and reduce harmful drug use among drug users. (f) The highest-priority research and action should nonetheless probably focus on social change rather than on changing drug users.

Keywords:  Sociopharmacology, Drug use, Harm reduction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0955-3959(02)00082-8

International Journal of Drug Policy
Volume 13, Issue 5 , Pages 341-347, November 2002